Brain Metastases, Adult
60
26
32
10
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.3%
5 terminated out of 60 trials
66.7%
-19.8% vs benchmark
2%
1 trials in Phase 3/4
30%
3 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (60)
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases
Preoperative vs Postoperative Hypofractionated Radiosurgery for Patients With Large Brain Metastases
Tarlatamab for SCLC Brain Metastases
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
Brain Imaging Biomarkers in Patients With Brain Metastasis
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
Study Comparing Neoadjuvant Versus Adjuvant Stereotactic Radiotherapy of Brain Metastases
Trial of Preoperative Radiosurgery Versus Postoperative Stereotactic Radiotherapy for Resectable Brain Metastases
Local Treatment Strategies for Brain Metastases of Colorectal Cancer
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Fractionated Stereotactic Radiotherapy for Limited Small Volume Brain Metastases
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
Keto-Brain:Investigating the Use of Ketogenic Diets in Brain Metastases
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
Multi-disciplinary Care for Brain Metastases
Ex Vivo Drug Response Evaluation for Next Generation Care of Brain Metastases
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases